官方服务：
资源简介：
Inhibition of EZH2 in THP-1 cells
应用场景：
创建时间：
2015-08-04
相关数据集
Epigenetic activation of plasmacytoid DC drives IFNAR-dependent therapeutic differentiation of AML [ATACseq DC]
Pharmacological inhibition of epigenetic enzymes can have therapeutic benefit against hematological malignancies. Apart from affecting tumor cell growth and proliferation, these epigenetic agents may
NIAID Data Ecosystem50
H3K27me3 and H3K4me3 ChIP-seq on DMSO or MAK683 treated cancer cell
The methyltransferase Polycomb Repressive Complex 2 (PRC2), composed of EZH2, SUZ12, and EED subunits, is associated with transcriptional repression via tri-methylation of histone H3 on lysine 27 resi
NIAID Data Ecosystem20
EZH2 suppresses the interferon-stimulated gene response in non-Hodgkin Lymphoma [RNA-seq]
Pharmacological inhibition of the histone lysine methyltransferase EZH2 has emerged as a therapeutic strategy for the treatment of non-Hodgkin Lymphoma (NHL), in particular for cases with mono-allelic
NIAID Data Ecosystem10
Epigenetic evidence of an Ac/Dc axis by VPA and SAHA. Epigenetic evidence of an Ac/Dc axis by VPA and SAHA
Valproic acid (VPA) is one of the most commonly used anti-epileptic drugs with pharmacological actions on GABA and blocking voltage-gated ion channels. VPA also inhibits histone deacetylase (HDAC) act
NIAID Data Ecosystem20
P300/CBP inhibition with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML [RNA-Seq]
Acute myeloid leukemia (AML) is a fatal blood cancer with cytotoxic chemotherapy offering at best 25% 5-year survival. While targeted BCL2 and FLT3 inhibitors venetoclax and gilteritinib are used upfr
NIAID Data Ecosystem10
